Medicinova Inc MNOV

$1.78 +0.15 (9.20%)

Valuation

Market cap
80,230,000
Revenue TTM
$410,000
Net income TTM
$-12,000,000
PE ratio
0.00
Forward PE
—
Profit margin
-2,926.83%
Debt to equity
0.00

Trading

Volume
275,000
Avg volume
394,752
Day's range
$1.67 – $1.84
Shares out
49,221,000
Stochastic %K
9%
Beta
0.61
Analysts
Strong Sell
Price target
$8.40

Price

Company profile

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis,...

Show more

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 373 1500
Website
https://medicinova.com
Address
4275 Executive Square, Suite 300, La Jolla, United States

Latest news

Stocktwits

BioTechHealthX Oct 3, 1:17 PM
$MNOV MediciNova develops therapies for serious diseases with unmet needs. Examine its MN-166 pipeline, $87.61 million market cap, and the costs of advancing clinical research. https://biotechhealthx.com/biotech-news/medicinova-mnov-at-1-78-puts-big-medical-questions-behind-a-small-price/
0 replies
BioTechHealthX Oct 3, 12:55 PM
$ICU $MNOV $OTLK $PDSB $RDHL Explore 10 healthcare stocks under $10 spanning cancer treatments, rare diseases, and medical devices, ranked by closing share price and daily percentage gain. https://biotechhealthx.com/biotech-news/top-10-healthcare-stocks-under-10-to-watch-now/
0 replies
Lionish Oct 3, 3:56 AM
$MNOV Reauthorization of ACT for ALS is now approved by congress. Cheers to ALS community and the environment for ALS drug developers like MNOV is getting more favorable. Just in time for MN-166.
0 replies
MarketDegenerate Oct 2, 6:46 PM
$MNOV — This one has a very straightforward upcoming catalyst. The blinded portion of the 234-patient COMBAT-ALS Phase 2b/3 trial is finished and MNOV is moving through database lock and analysis. Topline MN-166 ALS results are expected by year-end. For a biotech this size, that’s the kind of binary event that can completely change the valuation.
0 replies
MoneyMagnate Oct 2, 3:11 PM
$MNOV why is this climbing today after news that investment partners cut position? Seems like bad news to me
1 replies
MarketDegenerate Sep 30, 12:49 AM
$MNOV — COMBAT-ALS is the entire focus here now. All 234 patients have completed the blinded portion of the Phase 2b/3 MN-166 study and the company has moved into database lock and analysis. Topline ALS results are expected by year-end, giving MNOV a very clear upcoming binary catalyst.
0 replies
bioebi Sep 29, 2:28 PM
$MNOV $TENX$FLNA$APUS MNOV: ALS phase 2/3 results due in Q4 anticipation will send this skyrocketing and enough cash on hand
0 replies
Loosewin Sep 29, 5:10 AM
4/5 of $MNOV OCT16'26 2.5 PUT contracts assigned at $2.5, meaning $35 per contract profit but effectively buying $MNOV shares.
0 replies